Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 111 to 120 of 281 total matches.
Maribavir (Livtencity) for Cytomegalovirus Infection (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
ganciclovir/valganciclovir
(9.4% vs 33.9%).
DRUG INTERACTIONS — Maribavir is metabolized
primarily by CY3A4 ...
Maribavir (Livtencity – Takeda), an oral cytomegalovirus
(CMV) pUL97 kinase inhibitor, has been
approved by the FDA for treatment of post-transplant
CMV infection refractory to standard antiviral therapy
in patients ≥12 years old who weigh at least 35 kg.
Caplacizumab (Cablivi) for iTTP
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
, and urticaria were also reported with
use of the drug.
DRUG INTERACTIONS — Concomitant use of
caplacizumab ...
Caplacizumab-yhdp (Cablivi – Sanofi /Genzyme), a
von Willebrand factor-directed antibody fragment, has
been approved by the FDA for use in combination with
plasma exchange and immunosuppressive therapy
for treatment of immune-mediated thrombotic
thrombocytopenic purpura (iTTP; formerly called
acquired thrombotic thrombocytopenic purpura
[aTTP]) in adults. It is the first drug to be approved in
the US for this indication.
Fluvoxamine for COVID-19?
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
; 11:eaau5266.
5. Drug interactions from The Medical Letter. Available at:
www.medicalletter.org ...
A recent article in JAMA and an interview of its senior
author on 60 Minutes have heightened interest in
off-label use of the oral selective serotonin reuptake
inhibitor (SSRI) fluvoxamine (Luvox, and generics) to
treat COVID-19.
Orphengesic Forte - An Old Analgesic Combination Returns
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
as a prescription drug by the FDA for treatment of mild to moderate pain caused by acute musculoskeletal disorders ...
A fixed-dose combination of orphenadrine citrate, aspirin,
and caffeine (Orphengesic Forte – Galt; previously
available as Norgesic Forte) has been approved as
a prescription drug by the FDA for treatment of mild
to moderate pain caused by acute musculoskeletal
disorders. Single-ingredient generic orphenadrine
citrate is available by prescription in oral and injectable
formulations and has been used for years as an adjunct
for treatment of acute musculoskeletal pain. Orphengesic
Forte is being marketed as a non-opioid alternative for
pain relief.
Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
, cutaneous vasculitis,
and aplastic anemia have been reported with use of
the drug.
DRUG INTERACTIONS ...
The FDA has approved osimertinib (Tagrisso –
AstraZeneca), an oral kinase inhibitor, for adjuvant
treatment of non-small cell lung cancer (NSCLC)
after tumor resection in adults who have epidermal
growth factor receptor (EGFR) exon 19 deletions or
exon 21 L858R mutations. Osimertinib is the first
targeted therapy to be approved in the US for this
indication. The drug was previously approved for
first-line treatment of adults with NSCLC with EGFR
exon 19 deletions or exon 21 L858R mutations and for
treatment of EGFR T790M mutation-positive NSCLC
in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2 doi:10.58347/tml.2023.1682c | Show Introduction Hide Introduction
In Brief: Olaparib (Lynparza) for High-Risk Early Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
,
leukopenia, neutropenia, decreased appetite,
dysgeusia, dizziness, and stomatitis.
DRUG INTERACTIONS ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has been
approved by the FDA for adjuvant treatment of adults
with deleterious or suspected deleterious germline
BRCA-mutated (gBRCAm), human epidermal growth
factor receptor 2 (HER2)-negative, high-risk early
breast cancer who received prior neoadjuvant or
adjuvant chemotherapy. The drug was previously
approved for treatment of adults with deleterious
or suspected deleterious gBRCAm, HER2-negative
metastatic breast cancer who received chemotherapy
in the neoadjuvant, adjuvant, or metastatic...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e77-8 doi:10.58347/tml.2023.1674j | Show Introduction Hide Introduction
In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
, lymphopenia, dizziness, and abdominal pain
were also reported.
DRUG INTERACTIONS — Olaparib is metabolized ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor olaparib (Lynparza – AstraZeneca) has now
been approved by the FDA for use in combination
with abiraterone (Zytiga, and others) and either
prednisone or prednisolone for treatment of adults
with deleterious or suspected deleterious BRCA-mutated
(BRCAm) metastatic castration-resistant
prostate cancer (mCRPC). Olaparib was previously
approved by the FDA for treatment of adults with
deleterious or suspected deleterious germline or
somatic homologous recombinant repair (HRR) genemutated
mCRPC who progressed on prior treatment
with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 doi:10.58347/tml.2023.1679g | Show Introduction Hide Introduction
Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
should minimize their
use of any NSAID, including celecoxib.
DRUG INTERACTIONS — Concomitant use ...
Consensi (Coeptis/Burke), a fixed-dose combination
of the calcium channel blocker amlodipine (Norvasc,
and others) and the COX-2 selective NSAID celecoxib
(Celebrex, and generics), has been approved by the FDA
for treatment of patients who have hypertension and
osteoarthritis.
Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
month, every 2 weeks
for the next 2 months, and then every other month.
DRUG INTERACTIONS ...
Akeega (Janssen), a fixed-dose combination of
the oral poly(ADP-ribose) polymerase (PARP)
inhibitor niraparib (Zejula) and the antiandrogen
abiraterone acetate (Zytiga, and others), has been
approved by the FDA for use in combination with
prednisone for treatment of adults with deleterious
or suspected deleterious BRCA-mutated (BRCAm)
metastatic castration-resistant prostate cancer
(mCRPC). Niraparib has been available since 2017
for treatment of epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Abiraterone acetate has
been available since 2011 for treatment of CRPC...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e146-7 doi:10.58347/tml.2023.1684c | Show Introduction Hide Introduction
Ashwagandha Supplements
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
.
DRUG INTERACTIONS — Concurrent use of
ashwagandha and drugs with sedative properties ...
Ashwagandha is an herb extracted from the roots of
an evergreen shrub (Withania somnifera) found in
India that has been used as a "tonic" for centuries.
No specific constituent has been identified as an
active ingredient. Herbal supplements containing
ashwagandha, which is also known as winter cherry
and Indian ginseng, are widely promoted now in the
US for treatment of pain, anxiety, stress, fatigue, sleep
disturbances, cognitive decline, diabetes, arthritis,
male infertility, and various cancers.